Brain+ AS (OCSE:BRAINP) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 13, 2026)


What is Brain+ AS Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Brain+ AS's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

OCSE:BRAINP vs VEEV, BTSG, TEM: Margin of Safety % (DCF Earnings Based) Comparison

For the Health Information Services subindustry, Brain+ AS's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brain+ AS Margin of Safety % (DCF Earnings Based) vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Brain+ AS's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Brain+ AS's Margin of Safety % (DCF Earnings Based) falls into.


Brain+ AS Business Description

Address Svanevej 22, 2nd floor, Copenhagen, DNK, 2400
Brain+ AS is a digital therapeutics company. It is focused on developing and commercializing solutions for dementia care and with a primary focus on Cognitive Stimulation Therapy (CST). The company has developed a set of Digital Medicine technologies. Its product pipeline includes CST Therapist Companion, and CST Home Companion; CST Home Care; CST for Mild Cognitive Impairment (MCI). The company is developing Ayla, a scalable dementia care platform that provides software-based therapy and care solutions designed to support individuals with dementia.